MediciNova, Inc. (MNOV) Holdings Raised by Wells Fargo & Company MN

Wells Fargo & Company MN increased its position in shares of MediciNova, Inc. (NASDAQ:MNOV) by 63.3% in the third quarter, HoldingsChannel.com reports. The firm owned 32,575 shares of the biopharmaceutical company’s stock after acquiring an additional 12,624 shares during the quarter. Wells Fargo & Company MN’s holdings in MediciNova were worth $208,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Voya Investment Management LLC lifted its holdings in shares of MediciNova by 22.9% during the second quarter. Voya Investment Management LLC now owns 19,341 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 3,603 shares during the period. Teachers Advisors LLC lifted its holdings in shares of MediciNova by 7.2% during the second quarter. Teachers Advisors LLC now owns 54,649 shares of the biopharmaceutical company’s stock worth $287,000 after purchasing an additional 3,673 shares during the period. Rhumbline Advisers lifted its holdings in shares of MediciNova by 11.9% during the second quarter. Rhumbline Advisers now owns 36,273 shares of the biopharmaceutical company’s stock worth $191,000 after purchasing an additional 3,865 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in shares of MediciNova by 7.2% during the second quarter. TIAA CREF Investment Management LLC now owns 90,295 shares of the biopharmaceutical company’s stock worth $475,000 after purchasing an additional 6,035 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of MediciNova by 1.0% during the second quarter. Vanguard Group Inc. now owns 1,197,716 shares of the biopharmaceutical company’s stock worth $6,300,000 after purchasing an additional 12,249 shares during the period. 21.97% of the stock is owned by hedge funds and other institutional investors.

MediciNova, Inc. (MNOV) opened at $8.62 on Friday. MediciNova, Inc. has a 12-month low of $4.40 and a 12-month high of $11.45.

MNOV has been the subject of several recent research reports. BidaskClub upgraded MediciNova from a “hold” rating to a “buy” rating in a research report on Tuesday, January 30th. ValuEngine upgraded MediciNova from a “sell” rating to a “hold” rating in a research report on Wednesday.

TRADEMARK VIOLATION WARNING: “MediciNova, Inc. (MNOV) Holdings Raised by Wells Fargo & Company MN” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://sportsperspectives.com/2018/02/09/medicinova-inc-mnov-holdings-raised-by-wells-fargo-company-mn.html.

MediciNova Profile

Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).

Want to see what other hedge funds are holding MNOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MediciNova, Inc. (NASDAQ:MNOV).

Institutional Ownership by Quarter for MediciNova (NASDAQ:MNOV)

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply